The efficiency of progesterone vaginal gel versus intramuscular progesterone for luteal phase supplementation in gonadotropin-releasing hormone antagonist cycles: a prospective clinical trial

Fertility and Sterility

Volumn 94, Issue 2, 2010, Pages 761-763

  Kahraman, Semra ^a   Karagozoglu, S Hale ^a   Karlikaya, Guvenc ^a  

^a MEMORIAL HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; PROGESTERONE; PROGYNEX; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FETUS OUTCOME; GEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; SPOTTING;

ADMINISTRATION, INTRAVAGINAL; ADULT; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GELS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LUTEAL PHASE; OVULATION INDUCTION; PREGNANCY; PROGESTERONE; PROGESTINS; PROSPECTIVE STUDIES;

EID: 77953691644     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.10.004     Document Type: Article

References (19)

1. Smitz J., Erard P., Camus M., Devroey P., Tournaye H., Wisanto A., et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 7 (1992) 1225-1229
2. Tavaniotou A., Albano C., Smitz J., and Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with hMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 16 (2001) 663-667
3. Albano C., Grimbizis G., Smitz J., Riethmüller-Winzen H., Reissmann T., Van Steirteghem A., et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70 (1998) 357-359
4. de Jong D., Macklon N.S., and Fauser B.C. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 73 (2000) 1051-1054
5. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K., et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 88 (2003) 4186-4192
6. Kolibianakis E.M., Bourgain C., Platteau P., Albano C., Van Steirteghem A.C., and Devroey P. Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 80 (2003) 464-466
7. Tavaniotou A., and Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online 13 (2006) 326-330
8. Miles R.A., Paulson R.J., Lobo R.A., Press M.F., Dahmoush L., and Sauer M.V. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62 (1994) 485-490
9. Damario M.A., Goudas V.T., Session D.R., Hammitt D.G., and Dumesic D.A. Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil Steril 72 (1999) 830-836
10. Pritts E.A., and Atwood A.K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17 (2002) 2287-2299
11. Levine H. Luteal support in IVF using the novel vaginal progesterone gel Crinone 8%: results of an open-label trial in 1184 women from 16 US centers. Fertil Steril 74 (2000) 836-837
12. Schoolcraft W.B., Hesla J.S., and Gee M.J. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod 15 (2000) 1284-1288
13. Yanushpolsky E., Hurwitz S., Greenberg L., Racowsky C., and Hornstein M.D. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril 89 (2008) 485-487
14. Gibbons W.E., Toner J.P., Hamacher P., and Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril 69 (1998) 96-101
15. Ho C.H., Chen S.U., Peng F.S., Chang C.Y., and Yang Y.S. Luteal support for IVF/ICSI cycles with Crinone 8% (90 mg) twice daily results in higher pregnancy rates than with intramuscular progesterone. J Chin Med Assoc 71 (2008) 386-391
16. Chantilis S.J., Zeitoun K.M., Patel S.I., Johns D.A., Madziar V.A., and McIntire D.D. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril 72 (1999) 823-829
17. Romàn E., Aytoz A., Smitz J.E., Faguer B., Camus M., Van Steirteghem A.C., et al. Analysis of the bleeding pattern in assisted reproduction cycles with luteal phase supplementation using vaginal micronized progesterone. Hum Reprod 15 (2000) 1435-1439
18. Anserini P., Costa M., Remorgida V., Sarli R., Guglielminetti E., and Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective randomized study. Minerva Ginecol 53 (2001) 297-301
19. Dal Prato L., Bianchi L., Cattoli M., Tarozzi N., Flamigni C., and Borini A. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod Biomed Online 16 (2008) 361-367